Adès L, Guardiola P, Sociè G. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems. Blood Rev. 2002; 16:135–146.15 15. Majhail NS. Long‐term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017; 10:220–227.
16 16. Battiwalla M, Tichelli A, Majhail NS. Long‐term survivorship after hematopoietic cell transplantation: roadmap for research and care. Biol Blood Marrow Transplant. 2017; 23:184–192.
17 17. Socié G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003; 101:3373–3385.
18 18. Inamoto Y, Valdés‐Sanz N, Ogawa Y, et al. Ocular graft‐versus‐host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019; 54:662–673.
19 19. Deeg HJ, Flournoy N, Sullivan KM, et al. Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation. Int J Radiat Oncol Biol Phys. 1984; 10:957–964.
20 20. Tichelli A, Gratwohl A, Egger T, et al. Cataract formation after bone marrow transplantation. Ann Intern Med. 1993; 119:1175–1180.
21 21. Benyunes MC, Sullivan KM, Deeg HJ, et al. Cataracts after bone marrow transplantation: long‐term follow‐up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys. 1995; 32:661–670.
22 22. Belkacémi Y, Ozsahin M, Pène F, et al. Cataractogenesis after total body irradiation. Int J Radiat Oncol Biol Phys. 1996; 35:53–60.
23 23. Belkacemi Y, Labopin M, Vernant JP, et al. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys. 1998; 41:659–668.
24 24. Socié G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total‐body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long‐term follow‐up of 4 randomized studies. Blood. 2001; 98:3569–3574.
25 25. Gratwohl AA, Gratwhol AA, Moutsopoulos HM, et al. Sjögren‐type syndrome after allogeneic bone‐marrow transplantation. Ann Int Med. 1977; 87:703–706.
26 26. Mercier A, Devergie A, Arrago JP, et al. Systemic evaluation of Sjögren‐like syndrome after bone marrow transplantation in man. Transplantation. 1987; 43:677–679.
27 27. Jabs DA, Wingard J, Green WR, et al. The eye in bone marrow transplantation. III. Conjunctival graft‐vs‐host disease. Arch Ophthalmol. 1989; 107:1343–1348.
28 28. Tichelli A, Duell T, Weiss M, et al. Late‐onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) Working Party on Late Effects. Bone Marrow Transplant. 1996; 17:1105–1111.
29 29. Bacigalupo A, Chien J, Barisione G, Pavletic S. Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment. Semin Hematol. 2012; 49:15–24.
30 30. Bondeelle L, Bergeron A. Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation. Expert Rev Respir Med. 2019; 13:105–119.
31 31. Crawford SW, Fisher L. Predictive value of pulmonary function tests before marrow transplantation. Chest. 1992; 101:1257–1264.
32 32. Soubani AO, Miller KB, Hassoun PM. Pulmonary complications of bone marrow transplantation. Chest. 1996; 109:1066–1077.
33 33. Cerveri I, Fulgoni P, Giorgiani G, et al. Lung function abnormalities after bone marrow transplantation in children: has the trend recently changed? Chest, 120, 1900–1906.
34 34. Crawford SW, Pepe M, Lin D, et al. Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality. Am J Respir Crit Care Med. 1995; 152:690–695.
35 35. Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. New Engl J Med. 2014; 370:1820–1828.
36 36. McClune B, Majhail NS, Flowers MED. Bone loss and avascular necrosis of bone after hematopoietic cell transplantation. Semin Hematol. 2012; 49:59–65.
37 37. Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Am J Med. 1990; 89:733–738.
38 38. Socié G, Sélimi F, Sedel L, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors. Br J Haematol 1994; 86:624–628.
39 39. Socié G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). Br J Haematol. 1997; 97:865–870.
40 40. Fink JC, Leisenring WM, Sullivan KM, et al. Avascular necrosis following bone marrow transplantation: a case‐control study. Bone. 1998; 22:67–71.
41 41. Bizot P, Nizard R, Socié G, et al. Femoral head osteonecrosis after bone marrow transplantation. Clin Orthop Relat Res. 1998;( 357):127–134.
42 42. Campbell S, Sun C‐L, Kurian S, et al. Predictors of avascular necrosis of bone in long‐term survivors of hematopoietic cell transplantation. Cancer. 2009; 115:4127–4135.
43 43. Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000; 6:165–174.
44 44. Schimmer AD, Minden MD, Keating A. Osteoporosis after blood and marrow transplantation: clinical aspects. Biol Blood Marrow Transplant. 2000; 6:175–181.
45 45. Carpenter PA, Hoffmeister P, Chesnut CH, et al. Bisphosphonate therapy for reduced bone mineral density in children with chronic graft‐versus‐host disease. Biol Blood Marrow Transplant. 2007; 13:683–690.
46 46. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft‐versus‐host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft‐versus‐host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006; 12:375–396.
47 47. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288:321–333.
48 48. Rovó A, Tichelli A, Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Cardiovascular complications in long‐term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2012; 49:25–34.
49 49. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. New Engl J Med. 1989; 321:784–789.
50 50. Witherspoon RP, Deeg HJ, Storb R. Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplantation. 1994; 57:1413–1418.
51 51. Deeg HJ, Witherspoon RP. Risk factors for the development of secondary malignancies after marrow transplantation.
